Close Menu

NEW YORK (GenomeWeb) – OpGen will meet with a Nasdaq panel in early 2018 to stave off being delisted from the exchange, the company said in a regulatory document on Tuesday.

In a Form 8-K filing with the US Securities and Exchange Commission, OpGen said that it received written notice on Dec. 21 from Nasdaq informing the company that the exchange would be delisting its stock on Jan. 2, 2018 if it did not request a hearing with a Nasdaq Hearing Panel in relation to the firm's failure to meet certain listing requirements.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.